# AOD-9604 Peptide

> AOD-9604 is a human-growth-hormone fragment analog that targets fat metabolism, lipolysis, fat oxidation, and weight-regulation pathways.

Canonical: https://pepflow.app/peptides/aod-9604/

The GH Fragment

A synthetic analog of a human-growth-hormone C-terminal fragment, discussed for fat-metabolism biology rather than full growth-hormone replacement.

Weight loss

Tier E

Evidence Limited

Safety Limited Data

FDA status Not Approved

Last reviewed October 25, 2026 18 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is AOD-9604?

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone. It is discussed as a lipolytic or fat-metabolism peptide, not as full growth hormone replacement.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11146367/>)

Direct mechanistic support is mainly preclinical, including rodent studies of fat oxidation, lipolysis, and weight gain. Public human weight-loss support is much thinner than modern GLP-1 or incretin-drug evidence.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/11673763/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

The naming can be confusing: AOD-9604 is grouped with growth-hormone fragments, while the direct obesity literature is much smaller than approved obesity-drug evidence.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) For more context, read the [AOD-9604 preparation terminology guide](<https://pepflow.app/blog/how-to-reconstitute-aod-9604/>).

## What AOD-9604 is investigated for

AOD-9604 evidence is grouped by practical use case and injectable and intra-articular route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Fat breakdown and metabolism Mixed research context 32% Limited

The biology is plausible but not enough to support human weight-loss expectations.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

#### Human evidence

Published human efficacy support is weak and does not establish a reliable weight-loss effect.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

#### Animal / mechanistic evidence

Rodent and tissue studies support biological activity around lipolysis, beta-adrenergic signaling, and fat oxidation.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/11673763/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>)

### ### Cartilage repair and osteoarthritis Injectable 30% Limited

Cartilage repair has preclinical support for AOD-9604, but human osteoarthritis relief has not been established.[\[17\]](<https://pubmed.ncbi.nlm.nih.gov/26275694/>)

#### Human evidence

No human osteoarthritis data establish AOD-9604 as a joint-repair treatment.[\[17\]](<https://pubmed.ncbi.nlm.nih.gov/26275694/>)

#### Animal / mechanistic evidence

A rabbit collagenase-induced knee osteoarthritis model reported cartilage-regeneration signals after intra-articular AOD-9604, with stronger findings when combined with hyaluronic acid.[\[17\]](<https://pubmed.ncbi.nlm.nih.gov/26275694/>)

### ### Weight loss and fat loss Mixed research context 18% Insufficient

AOD-9604 is not a proven weight-loss or fat-loss peptide.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>)

#### Human evidence

Older clinical-development discussion does not establish reliable weight-loss or fat-loss improvement in humans.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>)

#### Animal / mechanistic evidence

Preclinical fat-metabolism findings explain the interest in fat loss, but they do not translate into a confident human result.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/11673763/>)

## Evidence snapshot

### Overall confidence

Limited

30%

AOD-9604 is not a high-confidence weight-loss peptide. The direct biology is mostly animal and mechanism work, while human efficacy support is weak and regulatory concerns are prominent.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

24%

### Human evidence

Insufficient

Public human weight-loss support is historically thin and does not establish a reliable obesity-treatment effect.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>)

44%

### Animal / preclinical

Limited

Rodent and tissue studies support biological activity around lipolysis, fat oxidation, and weight-gain models, but those findings do not establish human outcomes.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/11673763/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>)

42%

### Mechanism support

Limited

The mechanism rationale centers on a growth-hormone fragment domain and lipid-metabolism effects, with no modern clinical evidence package comparable to approved obesity drugs.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/11146367/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

## Forms & administration

AOD-9604 has oral, intravenous and experimental injectable formulations. Animal-only delivery approaches and current research-market injections differ in preparation and exposure. Their amounts cannot be transferred between formulations; human preparation and administration requirements remain incompletely established.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/26275694/>)

Injectable Intra-articular

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 250-500 mcg per dose. Oral protocols use about 1 mg per day.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Frequency

Injectable protocols usually use 1-2 doses daily. Oral protocols are usually once daily.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

### Timing Considerations

Common timing is morning or before a workout.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

### Cycle Length

Injectable cycles commonly run 8-12 weeks. Oral protocols run about 24 weeks.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

[Full AOD-9604 dosage guide](<https://pepflow.app/peptides/aod-9604/dosage/>)

## What to expect

### Early weeks

Early changes are more likely to look like ordinary weight fluctuation than a clear peptide-specific fat-loss effect.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

### 8-12 weeks

A clear waist or scale change is unlikely without matching nutrition and training changes, and human evidence does not support GLP-1-like weight-loss expectations.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

### Longer term

Large or reliable fat-loss effects remain unlikely on AOD-9604 alone; any visible change is more likely to be modest and hard to separate from the rest of the routine.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### After stopping

Weight and waist are likely to keep following nutrition, training, and baseline metabolic factors after the protocol ends, because AOD-9604 has not shown a durable reset effect in humans.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Safety profile

AOD-9604 safety handling is dominated by product and regulatory concerns: no approved product identified, FDA compounding safety risks, limited clinical usefulness, and explicit sports prohibition.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Cautions

- Immunogenicity risk[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Impurities and characterization[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- Athlete prohibited
- Pregnancy and special populations[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### What we don't know

Human long-term safety, dose-response, product purity, and route-specific risk remain unresolved.[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Who AOD-9604 is not for

Route-specific avoid and medical-review notes:

- **Competitive athletes**

  AOD-9604 is explicitly prohibited under WADA growth hormone fragment language.
- **Pregnancy and special populations**

  No approved label or robust human safety package supports use in pregnancy, breastfeeding, pediatric use, frailty, or complex endocrine disease.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Growth-hormone-axis products**

  Stacking AOD-9604 with growth hormone, GH secretagogues, or other weight-loss/metabolic drugs could compound or confuse appetite, weight, lipid, and adverse-effect signals; no human evidence establishes a safe or effective combination protocol.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Pairing notes

### Not recommended with

**GH, GHRH, GHRP, or metabolic fat-loss stacks** Mixed research context, Injectable

AOD-9604 has no validated human combination regimen with GH, GHRH, GHRP, or other weight-loss agents. Its injectable use has limited safety data, potential immunogenicity and impurity concerns, and serious adverse-event reports with unclear causality. Adding other agents introduces unstudied combination exposure, and AOD-9604 is prohibited in tested sport.[\[18\]](<https://www.fda.gov/media/183584/download>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Related peptides

[CJC-1295](<https://pepflow.app/peptides/cjc-1295/>) [CJC-1295 (no DAC)](<https://pepflow.app/peptides/cjc-1295-no-dac/>)

## Regulatory status

### United States

United States: not FDA-approved for human use as a drug. FDA also identifies compounded AOD-9604 safety concerns.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · Injectable AOD-9604 is not an FDA-approved human drug product.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) | Flagged · FDA lists compounded AOD-9604 among substances with potential safety risks, including immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, and limited safety information.[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[3\]](<https://www.fda.gov/media/94155/download>) |

### Injectable

FDA drug approval

Not Approved

Injectable AOD-9604 is not an FDA-approved human drug product.[\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

503A compounding

Flagged

FDA lists compounded AOD-9604 among substances with potential safety risks, including immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, and limited safety information.[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[3\]](<https://www.fda.gov/media/94155/download>)

### International

International status varies, but sports status is not ambiguous under WADA: AOD-9604 is named as a prohibited growth hormone fragment.

### Sports & competition

AOD-9604 is prohibited for athletes under WADA growth hormone fragment language, and WADA has issued specific public statements on the substance.[\[4\]](<https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604>)

## How it works

AOD-9604 is a growth-hormone fragment built around lipid-metabolism interest, not full GH replacement. The strongest signal is preclinical fat oxidation and lipolysis biology, which keeps the page in a low-confidence bucket.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/11673763/>)

That mechanism does not establish human fat loss. Older oral, injected, and experimental contexts are not interchangeable, and the obesity-development story did not become an approved therapy. Human usefulness remains the weak link.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[1\]](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>)

FDA compounding concerns and WADA growth-hormone-fragment language make the mechanism a caution point, not reassurance for self-use, stacking, tested athletes, or a clinical protocol.[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Research gaps & open questions

What the current literature has not yet settled about AOD-9604:

01

Peer-reviewed, placebo-controlled trials still need to show whether AOD-9604 produces meaningful, lasting weight loss in people and which dose and route were used.[\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

02

Each route needs direct studies of how the body handles AOD-9604, whether immune reactions occur, and what happens with long-term exposure; product purity also needs reliable testing.[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

03

For athletes, the practical unanswered question is how product contamination and use affect testing risk; the anti-doping rule is clearer than the weight-loss evidence.

## Common questions

### Is AOD-9604 the same as growth hormone?

No. It is a synthetic fragment analog related to the C-terminal region of human growth hormone, not full growth hormone replacement.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>)

### Does AOD-9604 work for weight loss?

Published evidence does not support strong human weight-loss confidence. Most direct support is preclinical, with weak public clinical usefulness compared with approved obesity drugs.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

### Is AOD-9604 banned in sport?

Yes. WADA explicitly names growth hormone fragments including AOD-9604 in the prohibited list.

## Myths & misconceptions

### Myth

Because AOD-9604 is only a fragment, it is automatically safe.

### Reality

A smaller fragment does not eliminate product-quality, immune, regulatory, or anti-doping risks. FDA specifically flags compounded AOD-9604 safety concerns.[\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

### Myth

Rodent fat-loss studies prove human fat loss.

### Reality

Rodent lipolysis and fat-oxidation findings are biological plausibility, not proof of meaningful human weight loss.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

### Myth

If it is not a steroid, it is not banned.

### Reality

WADA prohibits many peptide hormones, growth factors, related substances, and fragments; AOD-9604 is explicitly named.

## History & discovery

AOD-9604 moved from growth-hormone-fragment lipid-metabolism research into obesity-drug interest, then into anti-doping and compounding controversy. Its reputation grew wider than the human outcome evidence, so the useful history is cautionary.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

Early rodent and lipid-metabolism papers framed AOD-9604 as a synthetic growth-hormone fragment, and later development summaries described it as a metabolic obesity-drug candidate, but approval did not follow.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/10950816/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11713213/>) [\[9\]](<https://pubmed.ncbi.nlm.nih.gov/15134286/>) [\[10\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)

WADA and FDA materials shifted the practical history toward sports eligibility, product quality, and compounding risk rather than treating the early GH-fragment mechanism as clinical validation.[\[4\]](<https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604>) [\[2\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Published research 18 citations

- [\[1\] **openFDA Drugs@FDA query for AOD-9604** openFDA / U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22AOD-9604%22&limit=1>)
- [\[2\] **Certain bulk drug substances for use in compounding may present significant safety risks** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[3\] **Bulk drug substances nominated for use in compounding under section 503A** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[4\] **WADA statement on substance AOD-9604** World Anti-Doping Agency. regulatory.](<https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604>)
- [\[5\] **Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism** American Journal of Physiology-Endocrinology and Metabolism. animal.](<https://pubmed.ncbi.nlm.nih.gov/10950816/>)
- [\[6\] **Metabolic studies of a synthetic lipolytic domain of human growth hormone in obese Zucker rats** Endocrinology / metabolic research. animal.](<https://pubmed.ncbi.nlm.nih.gov/11146367/>)
- [\[7\] **The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism in obese mice** Endocrinology. animal.](<https://pubmed.ncbi.nlm.nih.gov/11713213/>)
- [\[8\] **Increase of fat oxidation and weight loss in obese mice caused by a fragment of human growth hormone** American Journal of Physiology-Endocrinology and Metabolism. animal.](<https://pubmed.ncbi.nlm.nih.gov/11673763/>)
- [\[9\] **AOD-9604 Metabolic** Drugs in R&D. review.](<https://pubmed.ncbi.nlm.nih.gov/15134286/>)
- [\[10\] **Obesity pharmacotherapy: current perspectives and future directions** Current Obesity Reports / PMC. review.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)
- [\[11\] **Detection and in vitro metabolism of AOD9604** Drug Testing and Analysis. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/25208511/>)
- [\[12\] **Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors** Obesity (Silver Spring, Md.), 2006. review.](<https://pubmed.ncbi.nlm.nih.gov/16931496/>)
- [\[13\] **Obesity drugs in clinical development** Current opinion in investigational drugs (London, England : 2000), 2006. review.](<https://pubmed.ncbi.nlm.nih.gov/16625817/>)
- [\[14\] **Gateways to clinical trials** Methods and findings in experimental and clinical pharmacology, 2005. review.](<https://pubmed.ncbi.nlm.nih.gov/15834452/>)
- [\[15\] **AOD-9604 does not influence the WADA hGH isoform immunoassay** Drug testing and analysis, 2013. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/24124033/>)
- [\[16\] **Current updates in the medical management of obesity** Recent patents on endocrine, metabolic & immune drug discovery, 2012. review.](<https://pubmed.ncbi.nlm.nih.gov/22435392/>)
- [\[17\] **Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model** Annals of Clinical and Laboratory Science, 2015. animal.](<https://pubmed.ncbi.nlm.nih.gov/26275694/>)
- [\[18\] **FDA evaluation of AOD-9604-related bulk drug substances** U.S. Food and Drug Administration, 2024-12-04. regulatory.](<https://www.fda.gov/media/183584/download>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

E

**Evidence**

30% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Flagged

**Citations**

[18 citations](<https://pepflow.app/peptides/aod-9604/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Fat breakdown and metabolism
- Cartilage repair and osteoarthritis
- Weight loss and fat loss

### Also known as

- AOD-9604
- AOD9604
- hGH fragment analog
- Tyr-hGH177-191

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Master How to Reconstitute AOD 9604 Safely](<https://pepflow.app/blog/how-to-reconstitute-aod-9604/>)
- [AOD-9604 dosage guide](<https://pepflow.app/peptides/aod-9604/dosage/>)
- [CJC-1295 Peptide](<https://pepflow.app/peptides/cjc-1295/>)
